Palvella Therapeutics completed a reverse merger with Pieris Pharmaceutical of Boston to become a public traded company, with ...

After losing a major partnership last year, the Boston biotech Pieris Pharmaceutical has been searching for a path forward.

status of deep veins before deciding about newer modality of laser treatment. Varicose veins could be due to simple valve ...

目前已经明确几乎所有BAVM的发生均与基因突变有关，因此 对BAVM患者及亲属进行基因筛查的必要性是目前需要迫切关注的问题 。研究数据表明，大约90%的散发BAVM病例的病因为KRAS或BRAF体细胞激活突变 [7] 。

Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company ...

The global neurovascular device market is projected to grow from USD 3.0 billion in 2024 to USD 3.9 billion by 2034, ...

There's been a rise in young and middle-aged U.S. adults experiencing catastrophic brain bleeds. A neurologist explains the ...

WAYNE, PA — Palvella Therapeutics, Inc. has completed its merger with Pieris Pharmaceuticals, Inc., forming a unified company ...

YORK, Maine — York Hospital announced the expansion of its vascular and vein care services, with the addition of a new team ...

Jamie Foxx revealed what everyone had been wondering about in a new Netflix special: the real reason that left him ...

However, high cost of neurovascular devices and dearth of qualified neurosurgeons required to handle these devices restrict growth of the market. Conversely, high growth rate exhibited by developing ...